Interleukin-6 production by U373 MG, a human astrocytoma cell line: different pathways involved in substance P and lipopolysaccharide activation

J Neuroimmunol. 1995 Jun;59(1-2):155-63. doi: 10.1016/0165-5728(95)00040-9.

Abstract

Substance P (SP) and lipopolysaccharide (LPS) stimulated interleukin-6 (IL-6) gene expression, as well as IL-6 protein secretion in the human astrocytoma cell line U373 MG. Staurosporine, an inhibitor of protein kinase C (PKC), entirely blocked SP- but not LPS-induced IL-6 release. In addition, the down regulation of PKC inhibited the SP response and only marginally altered LPS activation. Differently from SP, LPS-induced IL-6 release was markedly reduced by W7, a calmodulin antagonist. Moreover, SP interacted in a synergistic manner with LPS. Thus, neural (SP) and bacterial (LPS) mediators stimulate U373 MG IL-6 release via distinct, though not antagonistic, activation pathways.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkaloids / pharmacology
  • Astrocytoma / metabolism*
  • Bucladesine / pharmacology
  • Calcimycin / pharmacology
  • Cholera Toxin / pharmacology
  • Humans
  • Indomethacin / pharmacology
  • Interleukin-6 / biosynthesis*
  • Lipopolysaccharides / pharmacology*
  • Receptors, Neurokinin-1 / drug effects
  • Staurosporine
  • Substance P / pharmacology*
  • Sulfonamides / pharmacology
  • Tetradecanoylphorbol Acetate / pharmacology
  • Tumor Cells, Cultured

Substances

  • Alkaloids
  • Interleukin-6
  • Lipopolysaccharides
  • Receptors, Neurokinin-1
  • Sulfonamides
  • Substance P
  • Calcimycin
  • Bucladesine
  • W 7
  • Cholera Toxin
  • Staurosporine
  • Tetradecanoylphorbol Acetate
  • Indomethacin